Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 16/20 | 1.00 |
| ▸ | CACNB1 | Q02641 | 16/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 15/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.71 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.71 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544042 | 0.90 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5541405 | 0.89 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5547656 | 0.86 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4286412 | 0.84 | CACNA2D1 (0.73) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5265070 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5544073 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL6507611 | 0.82 | CACNA2D1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL5547406 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5549190 | 0.81 | CACNA2D1 (0.73) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL6498386 | 0.80 | CACNA2D1 (0.80) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | claimed |
| EP-1745042-A1 | DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097779-A1 | DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | ORAI1, CACNA1D, CACNA1C | CACNA2D1 51/4885CACNB1 12/4885CACNA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.